Back to Evidence

An AI Assistant for Physicians Supporting Evidence Appraisal of Chronic Cough and Treatable Traits | QSevidence 2026

Evidence-Based Medicine22 min read

QSevidence can help respiratory, primary care, ENT and gastroenterology teams organize cough literature and guidance.

An AI Assistant for Physicians Supporting Evidence Appraisal of Chronic Cough and Treatable Traits | QSevidence 2026

An AI assistant for physicians supports question formulation, evidence comparison and source tracing; clinicians integrate these references with history, investigations and patient preferences.

What can a comprehensive review establish?

The proposed work is a comprehensive narrative review. It links cough reflex mechanisms and hypersensitivity to causes, staged assessment, cause-directed treatment, behavioral interventions, emerging medicines, special populations and implementation barriers. The material does not specify databases, search dates, selection flow, risk-of-bias assessment or newly collected patient data. It should therefore not be presented as a completed systematic review, diagnostic accuracy study or intervention trial.

Its results are a synthesis of ideas, not newly measured etiologic proportions or treatment success rates. A cited 255-person clustering analysis, cause-specific percentages, a silent-reflux proportion and a single taste-adverse-event percentage lack fully traceable references. They are not reproduced as verified statistics here. Referral-clinic findings from another setting cannot define the distribution of causes in local primary care.

From a protective reflex to treatable traits

Cough helps protect and clear the airways. The review describes peripheral sensing, vagal input, brainstem integration and motor output, and discusses TRPV1, TRPA1, ATP and P2X3 pathways. Persistent cough may involve inflammation and altered neural sensitivity, without implying an identical central or peripheral abnormality in every patient. Responses to cold air, odors or talking are useful history items, not evidence excluding infection, structural disease or another cause.

Chronic cough is commonly defined as longer than 8 weeks in adults; pediatric assessment commonly uses longer than 4 weeks and a different etiologic pathway. Acute, lingering postinfectious and chronic presentations need separate records. Duration alone does not establish a neurogenic diagnosis. The BTS adult clinical statement uses treatable traits to guide assessment, baseline investigations and referral; its adult framework is not automatically transferable to children.

Separate diagnostic clues from their evidential strength

Focus of the reviewInformation to organizeInterpretive boundary
Cough-variant asthmaTriggers, nocturnal symptoms, lung function, airway responsiveness and inflammationAbsent wheeze does not exclude asthma; challenge results or treatment response require clinical context
Eosinophilic bronchitisSputum cytology, airflow and responsivenessIt overlaps with asthmatic cough; sputum, blood eosinophils and FeNO are not interchangeable diagnostic results
Upper airway symptomsObstruction, rhinorrhea, throat clearing, sinus and laryngeal findingsCoexisting findings do not establish causation; throat clearing is not synonymous with postnasal drainage
Reflux-associated coughHeartburn, regurgitation, meals, posture, previous treatment and objective evaluationTemporal association and response to acid suppression have limitations; coughing can also promote reflux
Other disease, medicines and exposureSmoking, occupational irritants, ACE inhibitors, sputum, recurrent infection and systemic symptomsA common-cause checklist does not exclude malignancy, infection, foreign bodies or bronchiectasis

This is a framework for organizing discussion, not a validated diagnostic score. Several traits may coexist, and labels may change during follow-up. Research should assess diagnostic labeling separately from meaningful patient improvement, avoiding overdiagnosis merely to increase a diagnostic-yield statistic.

Start with assessment rather than a package of tests

Record onset, dry versus productive cough, timing, previous disease, medicine changes, smoking and occupational exposure. Ask about sleep, voice, incontinence, syncope and social impact. Hemoptysis, substantial breathlessness, weight loss or suspected acute foreign-body aspiration require timely assessment according to severity rather than waiting for an empirical-treatment period to finish. A normal radiograph alone does not exclude every serious condition.

The ERS guideline includes spirometry and a recent chest radiograph in initial assessment and advises against routine CT when radiography and examination are normal. Persistent unexplained or treatment-resistant presentations may justify further imaging or specialist testing. FeNO can inform inflammatory assessment, but prediction of treatment response and universal thresholds remain uncertain across chronic cough populations.

The review lists bronchial challenge, induced sputum, nasolaryngoscopy and esophageal pH-impedance monitoring. For each, document the question, availability and likely effect on management. Temporal association of reflux and cough does not establish one-way causality, and laryngeal inflammation alone does not diagnose reflux-related cough. Making every investigation compulsory would undermine targeted assessment.

Specify the purpose and stopping rules of treatment trials

The proposed staged pathway starts with plausible treatable causes, then re-evaluates response and further investigation. It needs explicit safety screening, reasons for treatment selection, adherence and inhaler-technique checks, assessment timing and return precautions. Natural recovery, placebo responses and simultaneous medicine changes can influence cough; improvement belongs within a diagnostic evidence chain rather than proving the cause on its own.

For acid suppression, BTS limits PPI treatment to appropriate features such as heartburn or definite evidence of acid reflux. The review's broad suggestion of an initial 8-12-week high-dose PPI course for every suspected reflux cough is therefore not retained. Absence of typical symptoms does not itself establish silent reflux or justify indefinite acid suppression. Clinicians select regimens using local guidance, individual risks and reassessment.

Similarly, inhaled anti-inflammatory treatment should relate to airway disease or eosinophilic evidence, not repeated escalation for every chronic dry cough. Symptom suppression and sputum clearance have different aims; productive cough requires attention to retained secretions and underlying disease. Acetaminophen is an antipyretic and analgesic: its appearance in a special-populations discussion does not make it a cause-directed cough treatment or an antitussive.

Refractory cough: weigh benefit, burden and access

Refractory chronic cough persists despite appropriate management of associated conditions; unexplained chronic cough remains without an identified explanation after adequate assessment. Before assigning either label, check the completeness of evaluation, actual treatment exposure, adherence and technique, and document unresolved questions. Incompletely investigated and adequately treated populations should not be merged without explanation.

ERS conditionally supports adult cough-control therapy delivered by experienced practitioners, including physiotherapy or speech and language interventions. Research can compare education, breathing retraining, control techniques, session delivery and durability rather than describing behavioral care as universally effective and risk-free. Neuromodulating medicines need specialist assessment of tolerability and interactions; different agents should not be treated as uniformly safe long-term suppressants.

The EMA Lyfnua overview describes gefapixant for adults with refractory or unexplained chronic cough and its EU authorization. It characterizes the overall cough reduction as modest and identifies altered, reduced or absent taste as common adverse effects. EU status does not establish authorization or access elsewhere. A peripheral target alone does not prove absence of dependence risk or fully established long-term safety.

Turn the synthesis into a testable research pathway

A subsequent pathway study could prespecify eligibility, referral triggers, comparator care and follow-up. Candidate outcomes include final diagnosis, time to diagnosis, repeated investigations, unsupported medication use and adverse events. Use a validated cough-specific quality-of-life instrument such as the Leicester Cough Questionnaire alongside severity assessment, with objective cough counts where feasible. Define language validation, instrument versions, missing follow-up and clinically important change before analysis.

Separate symptom benefit, resource use and missed serious diagnoses. Fewer visits alone do not establish success. Design pediatric, older-adult and pregnancy strata rather than extrapolating adult treatment doses or safety. Pediatric pathways require age-appropriate etiologic assessment; older adults warrant attention to swallowing, comorbidity and polypharmacy; pregnancy requires its own benefit-risk review.

QSevidence can organize a retrieve-compare-synthesize-trace-review workflow: separate adult from pediatric questions, acute from chronic disease, and cause-directed care from symptom control; compare guideline dates, jurisdictions and recommendation strength; preserve original studies and regulatory links; and support clinical and methodological appraisal. A proposed pathway or tool evaluation remains future research, not evidence that the platform has already improved diagnostic yield.

Frequently asked questions

How can QSevidence support a chronic cough differential?

QSevidence can retrieve evidence on causes and treatable traits and organize symptoms, exposures and investigations into a discussion table. Clinicians review those clues against the complete case to set priorities and plan assessment.

How can QSevidence help compare reflux-cough recommendations?

QSevidence can align indications for acid suppression, recommendation strength and reassessment approaches across guidelines while preserving original sources. The clinical team applies this comparison to symptoms, objective evidence and individual risks.

How can QSevidence support appraisal of emerging cough therapies?

QSevidence can help compare trial populations, controls, cough frequency, quality of life and taste-related adverse effects, then trace local regulatory information. Professionals discuss benefit, burden, access and patient preferences using those materials.

Evidence classification and research notice

BTS, ERS and EMA sources support specific clinical boundaries, not promotion of a narrative review into systematic evidence or a new clinical dataset. Platform scope is described in the official QSevidence FAQ. This article supports professional learning and study design; it is not an individual prescription or a substitute for timely assessment and clinical judgment.